CA2628747C - Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer - Google Patents

Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer Download PDF

Info

Publication number
CA2628747C
CA2628747C CA2628747A CA2628747A CA2628747C CA 2628747 C CA2628747 C CA 2628747C CA 2628747 A CA2628747 A CA 2628747A CA 2628747 A CA2628747 A CA 2628747A CA 2628747 C CA2628747 C CA 2628747C
Authority
CA
Canada
Prior art keywords
cancer
hormone therapy
patient
hormone
term
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2628747A
Other languages
English (en)
French (fr)
Other versions
CA2628747A1 (en
Inventor
Jordan S. Fridman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CA2628747A1 publication Critical patent/CA2628747A1/en
Application granted granted Critical
Publication of CA2628747C publication Critical patent/CA2628747C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2628747A 2005-11-22 2006-11-21 Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer Active CA2628747C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73891905P 2005-11-22 2005-11-22
US60/738,919 2005-11-22
PCT/US2006/045151 WO2007062093A2 (en) 2005-11-22 2006-11-21 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor

Publications (2)

Publication Number Publication Date
CA2628747A1 CA2628747A1 (en) 2007-05-31
CA2628747C true CA2628747C (en) 2014-01-21

Family

ID=37994504

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2628747A Active CA2628747C (en) 2005-11-22 2006-11-21 Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer

Country Status (5)

Country Link
US (1) US8324194B2 (enExample)
EP (1) EP1951242A2 (enExample)
JP (1) JP5256042B2 (enExample)
CA (1) CA2628747C (enExample)
WO (1) WO2007062093A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP2264030A1 (en) * 2003-10-17 2010-12-22 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
US20100332417A1 (en) * 2009-06-02 2010-12-30 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP4149547A4 (en) 2020-05-13 2024-08-14 Adagene AG Compositions and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
EP1377298B1 (en) 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
WO2004089294A2 (en) * 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
EP1622569B1 (en) * 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP2264030A1 (en) * 2003-10-17 2010-12-22 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

Also Published As

Publication number Publication date
EP1951242A2 (en) 2008-08-06
US8324194B2 (en) 2012-12-04
CA2628747A1 (en) 2007-05-31
US20070117809A1 (en) 2007-05-24
JP2009516747A (ja) 2009-04-23
WO2007062093A3 (en) 2008-10-23
WO2007062093A2 (en) 2007-05-31
JP5256042B2 (ja) 2013-08-07

Similar Documents

Publication Publication Date Title
US8324194B2 (en) Combination therapy for the treatment of cancer
JP5707518B2 (ja) 置換型キノリン化合物及び使用方法
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
JP2022500379A (ja) 組み合わせ療法
AU2016264034B2 (en) Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
JP2022500388A (ja) 組み合わせ療法
WO2000035455A1 (en) Heteroaryl-aryl ureas as igf-1 receptor antagonists
TWI285550B (en) s for combating menopausal hot flushes Use of CGRP antagonists and CGRP release inhibitor
WO2017040982A1 (en) Her3 ligands and uses thereof
CN104349779A (zh) Pi-3激酶抑制剂的剂量方案
CN101495147B (zh) 药物组合
AU2017264839B2 (en) 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
AU2017285609A1 (en) Compositions for treating or preventing vasomotor symptoms
CN102227227A (zh) 包含吡啶并[4，3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合
AU2008309562A1 (en) Isoxazole compound for the treatment of cancer
JP7130180B2 (ja) 子宮内膜症の処置のためのインドールの新規誘導体
AU2020215684B2 (en) 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
CN111356478A (zh) Ezh2抑制剂组合疗法
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
US20130267512A1 (en) Jnk inhibitors for the treatment of endometriosis
WO2024206147A1 (en) Dosage regimens of estrogen receptor degraders
KR20250046197A (ko) 티오벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
WO2023224961A1 (en) Cancer therapy using a combination of a cdk7 inhibitor with an oral serd

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241107

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260603